Incretin receptor agonists are peptides studied for how they act on the gut-hormone receptors involved in metabolism — GLP-1, GIP and glucagon. This guide explains the class and how single, dual and triple agonists differ. All are research-use-only compounds — not for human use.
- Incretins are gut hormones that influence insulin release after eating.
- Receptors studied: GLP-1, GIP and glucagon.
- Generations: single → dual → triple agonists, by how many receptors they engage.
- Status: some are approved drugs; research-grade material is for laboratory use only.
The receptors
Three receptors define this research area. GLP-1 and GIP are the two classic “incretin” pathways; the glucagon receptor is a third metabolic target that newer compounds add.
| Design | Receptors engaged | Example |
|---|---|---|
| Dual agonist | GLP-1 + GIP | Tirzepatide |
| Triple agonist | GLP-1 + GIP + glucagon | Retatrutide |
From dual to triple
The research story of this class is about engaging more pathways at once. Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds glucagon-receptor activity to make a triple agonist. For a direct comparison, see Tirzepatide vs Retatrutide.
- GLP-1 receptor — the core incretin pathway.
- GIP receptor — the second incretin pathway (dual agonists).
- Glucagon receptor — the third target (triple agonists).
Research status
Some compounds in this class are the basis of FDA-approved medications, while others are investigational. Material sold here is research-grade and intended only for laboratory research — not for human use. Nothing here is a health claim or recommendation for use.
Browse GLP-1 research compounds
Lab-tested, with third-party purity verification.